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Abstract
Airway remodeling is an important process in response to repetitive inflam-
matory-mediated airway wall injuries. This is characterized by profound
changes and reorganizations at the cellular and molecular levels of the lung
tissue. It is of particular importance to understand the mechanisms involved
in airway remodeling, as this is strongly associated with severe asthma leading
to devastating airway dysfunction. In this study, we have investigated the
transforming growth factor-b (TGFb, a proinflammatory mediator)-activated
fibroblast to myofibroblast transdifferentiation pathway, which plays a key role
in asthma-related airway remodeling. We show that TGFb induces fibroblast
to myofibroblast transdifferentiation by the expression of aSMA, a specific
myofibroblast marker. Furthermore, Smad2/Smad3 gene and protein expres-
sion patterns are different between fibroblasts and myofibroblasts. Such a
change in expression patterns reveals an important role of these proteins in
the cellular phenotype as well as their regulation by TGFb during cellular
transdifferentiation. Interestingly, our data show a myofibroblastic TGFb-
mediated increase in glucocorticoid receptor (GR) expression and a preferen-
tial localization of GR in the nucleus, compared to in fibroblasts. Further-
more, the GRb (nonfunctional GR isoform) is increased relative to GRa
(functional isoform) in myofibroblasts. These results are interesting as they
support the idea of a GRb-mediated glucocorticoid resistance observed in the
severe asthmatic population. All together, we provide evidence that key players
are involved in the TGFb-mediated fibroblast to myofibroblast transdifferenti-
ation pathway in a human lung fibroblast cell line. These players could be the
targets of new treatments to limit airway remodeling and reverse glucocorti-
coid resistance in severe asthma.
Introduction
Airway remodeling refers to the structural modifications
of the normal architecture of the airway wall. Such tissue
reorganization involves changes in the composition and
the organization of its cellular and molecular constituents
contributing to the thickening of airway walls (Kuwano
et al. 1993; James 1997). Airway remodeling has been
attributed to repetitive injury to the airway wall arising
from cycles of inflammation such as during repair, and
asthma (Ganesan and Sajjan 2013). One of the main
structural changes observed during remodeling includes
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the transdifferentiation of fibroblasts into myofibroblasts.
Since myofibroblasts are practically absent in normal air-
ways, fibroblast to myofibroblast transdifferentiation is
therefore one of the key events contributing to the
chronic sequel of asthma (Hackett et al. 2009), ultimately
leading to permanently impaired pulmonary function
(Pascual and Peters 2005).
Transforming growth factor-b (TGFb) exerts multiple
essential biological functions. Importantly, it plays a
major role in lung function and in the pathogenesis of
pulmonary diseases. Dysregulations in TGFb cellular
pathway have been implicated in numerous chronic lung
conditions, including asthma. Indeed, its expression has
been shown to be increased in chronic lung diseases (Vig-
nola et al. 1997). Interestingly, studies suggest that TGFb
expression is upregulated in asthmatic lungs (Redington
et al. 1997; Vignola et al. 1997; Tillie-Leblond et al. 1999;
Chu et al. 2000). In the lung, TGFb is involved in airway
remodeling (Desmouliere 1995; Doherty and Broide
2007). It has been shown to promote fibroblast to myofi-
broblast transdifferentiation and to trigger their prolifera-
tion (Michalik et al. 2009). Therefore, taken together,
these studies suggest that TGFb is tightly associated with
asthma-related airway remodeling.
The major signaling pathway of TGFb is through its
transmembrane serine/threonine kinase receptor (Nakao
et al. 1997; Attisano and Wrana 2000; ten Dijke et al.
2000; Massague and Chen 2000; Massague and Wotton
2000; Shi and Massague 2003). Activated TGFb receptor
stimulates the phosphorylation of cytoplasmic receptor-
regulated Smad proteins. The activated Smad2 and Smad3
proteins form complexes, which subsequently translocate
and accumulate in the nucleus, where they regulate the
transcription of target genes. Recent studies show that
TGFb-induced transdifferentiation of fibroblasts into
myofibroblasts is characterized by the induction of alpha-
smooth muscle actin (aSMA) by the Smad complex (Des-
mouliere et al. 1993; Ronnov-Jessen and Petersen 1993;
Roy et al. 2001). Therefore, aSMA is commonly used to
define the myofibroblastic phenotype, whereas vimentin,
an intermediate cytoplasmic filament protein, is routinely
used as nonspecific marker for both fibroblasts and
myofibroblasts (McAnulty 2007).
Glucocorticoids are the most potent anti-inflammatory
drugs used in the treatment of inflammatory diseases such
as asthma (Donohue and Ohar 2004; Raissy et al. 2013).
Their cellular effects are mediated by the glucocorticoid
receptor (GR). In the absence of ligand, GR is primarily
cytoplasmic; while following ligand binding, it translo-
cates to the nucleus, where it induces or represses the
transcription of specific target genes (Galon et al. 2002;
Lu et al. 2007; Ren et al. 2012). Glucocorticoids are the
most effective anti-inflammatory medication for the
treatment of asthma. Unfortunately, asthma resistance to
glucocorticoids has been observed and such glucocorti-
coid resistance is a major barrier to the treatment of sev-
ere asthma (Holgate and Polosa 2006; Jarjour et al. 2012).
Numerous studies have proposed a role for GR iso-
forms in steroid resistance (Hamid et al. 1999; Sousa
et al. 2000). The two major GR isoforms, GRa and GRb,
are generated through alternative splicing. While GRa
mediates the actions of glucocorticoids leading to GR-
mediated cellular response, GRb does not bind glucocor-
ticoid agonists, limiting glucocorticoids-mediated target
gene transcription regulation (Bamberger et al. 1995;
Pujols et al. 2007). Therefore, when both GR splice vari-
ants are coexpressed, GRb acts as a dominant negative
inhibitor and antagonizes the activity of GRa (Bamberger
et al. 1995; Yudt et al. 2003). This ability of GRb to inhi-
bit GRa activity suggests that increased levels of GRb
could lead to glucocorticoid resistance (Sousa et al. 2000;
Boardman et al. 2014).
Given the importance of fibroblast to myofibroblast
transdifferentiation in airway diseases, we set out to
investigate the TGFb molecular pathways in fibroblasts
and myofibroblasts using a human lung fibroblast cell
line (WI-38). Here we use WI-38 treated with TGFb to
induce fibroblast to myofibroblast transdifferentiation or
left untreated to demonstrate that TGFb signaling path-
way is affected in myofibroblasts. TGFb-treated myofi-
broblasts exhibit decreased Smad3 gene and protein
expression. We also provide molecular evidence for a
role of GRb in glucocorticoid resistance in asthma-like
cells.
Materials and Methods
Antibodies
The primary antibodies for the following proteins were
used for western blot analysis and immunofluorescence
(IF): aSMA (ab7817, Abcam), a/b-Tubulin (2148, Cell
Signaling Technology), GR (sc-8992, Santa Cruz Biotech-
nology), Smad2/3 (sc-133098, Santa Cruz Biotechnology),
Vimentin (sc-5565, Santa Cruz Biotechnology).
Cell culture
Human embryonic lung fibroblasts, WI-38 cell line, were
obtained from the European Collection of Cell Cultures
(ECACC, Ref No 90020107). Cells were grown in DMEM
(Life Technologies, Carlsbad, CA) supplemented with
10% fetal bovine serum (FBS; Bovogen, Australia) and
antibiotics (penicillin, streptomycin, neomycin; Life Tech-
nologies) at 37°C in a humidified atmosphere of 5%
CO2.
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TGFb1 treatment
At day 0 cells were either seeded in 35 mm Petri dishes
(for day 1 collection, D1) or maintained in 25 cm2 flasks
for later collection (when myofibroblast transdifferentia-
tion was obtained). Cells were incubated in DMEM with
10% FBS, antibiotics and 2–5 ng/mL TGFb1 (R&D sys-
tems, Minneapolis, MN). TGFb1 supplemented media
was changed every second day until collection. Myofi-
broblast phenotype was confirmed by western blot and
immunofluorescence for aSMA. Once transdifferentiation
was achieved cells were collected for further analysis with
respective untreated controls (see below for determination
of fibroblast to myofibroblast transdifferentiation). Sam-
ples were labelled as follow D1 or D20 WI-38 +TGFb
(with) or -TGFb (without).
Western blot analysis
Overnight confluent cultures of WI-38  TGFb1 were
collected for protein extraction at the specified time
points. Whole-cell lysates were collected in RIPA buffer
(150 mmol/L NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 50 mmol/L Tris, with protease
and phosphatase inhibitors). Then, protein extracts were
heated at 90°C for 5 min in Laemmli buffer prior to
SDS-PAGE. Cell lysates were subjected to SDS-polyacry-
lamide electrophoresis followed by transfer to nitrocellu-
lose membranes in Tris-glycine-ethanol buffer
(25 mmol/L Tris-HCl, 192 mmol/L glycine, 20% etha-
nol). Blots were stained with Ponceau S (Sigma, St
Louis, MO) to confirm proteins transfer and then
blocked for 1 h in PBS Odyssey Blocking Buffer contain-
ing 0.1% Tween 20 or 2.5% skim milk in PBS-T
(10 mmol/L Na2HPO4, 1.7 mmol/L KH2PO4, 2.7 mmol/
L KCl, 137 mmol/L NaCl, 0.1% Tween 20), prior to
incubation with different primary antibodies diluted in
PBS Odyssey Blocking Buffer containing 0.1% Tween 20
or 2.5% skim milk in PBS-T overnight at 4°C. Primary
antibodies were detected using LI-COR IRDye Infrared
Dye (1:15000) or horseradish peroxidase (HRP; 1:5000)
secondary antibodies. Detection of HRP bound
antibodies was performed with enhanced chemilumines-
cence (Perkin Elmer, Waltham, MA). Blots were visual-
ized using the Odyssey Fc Infrared Imager (LI-COR
Biotechnology, NE) and quantified by densitometry
using Image Studio software (LI-COR, NE). Results are
expressed as relative to corresponding a/b-tubulin and
normalized to D1 WI-38 -TGFb, which constitutes our
control group. Where required, blots were stripped (2%
SDS, 62.5 mmol/L Tris-HCl, 114.4 mmol/L b-mercap-
toethanol) at 50°C for 10 min, washed and reprobed.
mRNA analysis by real-time PCR
Total RNA was extracted from overnight confluent cul-
tures of WI-38  TGFb1 using TRI Reagent (Sigma),
first-strand cDNA synthesized from 1 lg RNA (High-
Capacity cDNA Reverse Transcription Kit, Life Tech-
nologies) and cDNA for aSMA, GAPDH, GR, Smad2,
Smad3 (see Table 1 for description of primer sequences)
estimated by semiquantitative real-time PCR using Bio-
Rad CFX96 (Bio-Rad, CA). Data were analyzed using
CFX Manager Software version 3.1 (Bio-Rad), and is
presented relative to GAPDH and normalized to D1 WI-
38 -TGFb.
Immunofluorescence (IF)
Overnight confluent cultures of WI-38  TGFb1 were
grown on glass coverslips. Cells were fixed in 4%
formaldehyde for 10 min and blocked/permeabilized in
2% BSA containing 0.5% Triton X-100 for 10 min. Cells
were then incubated with primary antibodies overnight at
4°C and bound antibodies were detected by Alexa Fluor
conjugated secondary antibodies (1:1000; Life Technolo-
gies). Coverslips were mounted on slides in ProLong Gold
reagent with DAPI (Life Technologies). Samples were
examined under a Nikon Ti Eclipse confocal laser-scan-
ning microscope (CLSM) with Nikon 60x/1.40 oil immer-
sion lens (Plan Apo VC OFN25 DIC N2; optical section
of 0.5 lm) and the NIS Elements AR software (Nikon
Corporation, Japan). ImageJ 1.48v shareware (courtesy of
Wayne Rasband, NIH) was used to analyze the digital
Table 1. Primer sequences used for semiquantitative real-time PCR analyses.
Gene Forward primer Reverse primer
aSMA TTATGTTTGAGACTTTCAATGTC GTCCAGAGGCATAGAGAG
GAPDH TGGTATGACAACGAATTTGG TCTACATGGCAACTGTGAGG
GR GATGTCATTATGGAGTCTTAACTT TTGTGCTGTCTACCTTCC
Smad2 GCTTTACAGACCCATCAAAT CCTCTTCCTATATGCCTTCT
Smad3 CTACCAGTTGACCCGAAT CAGTCTGTCTCCTGTACTC
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images to determine the relative intensity of fluorescence
in the nucleus (Fn) and in the cytoplasm (Fc) in order to
estimate the nucleus-cytoplasm fluorescence ratio (Fn/c
ratio) after the subtraction of background fluorescence.
Fn and Fc intensities were measured from 40 cells in each
experimental condition.
Myofibroblast determination
It is well accepted that cell expression of aSMA is a speci-
fic marker of fibroblast to myofibroblast transdifferentia-
tion, whereas vimentin is considered as a nonspecific
fibroblast and myofibroblast marker (McAnulty 2007).
Therefore, we used aSMA and vimentin antibodies to
determine fibroblast to myofibroblast transdifferentiation
by IF and western blot analysis. In this study, we defined
fibroblast to myofibroblast transdifferentiation using the
following criteria: (1) coexpression of aSMA and vimen-
tin should be observed in cells using IF staining and (2)
TGFb-treated samples with positive aSMA IF staining
should be associated with at least a fivefold increase in
aSMA expression.
Statistical analyses
Data are presented as mean  SEM for all experiments.
From these experiments, statistical analysis was per-
formed setting the level of statistical significance at
P < 0.05. Statistical analysis was performed using two-
way ANOVA followed by correction for multiple com-
parisons using Sidak’s test in Prism 6 software (Graph-
Pad software, CA). Data were grouped by treatment and
time.
Results
Effect of TGFb treatment on aSMA and
vimentin expression in human lung
fibroblasts and myofibroblasts
TGFb plays a key role in airway remodeling, partly due to
its capacity to induce fibroblast to myofibroblast transdif-
ferentiation. Therefore, we first examined that TGFb
treatment could induce such a transdifferentiation in WI-
38 cell line. Vimentin protein expression was measured at
all timepoints (D1, D10, D15, and D20) and no signifi-
cant change in its expression was observed through the
treatment period (Two-way ANOVA: P = 0.85; n = 3 in
each group; Fig. 1A). Upon TGFb stimulation, WI-38
showed a significant change in aSMA protein expression
compared to untreated cells (Two-way ANOVA:
P = 0.0006; n = 3 in each group; Fig. 1B). Furthermore,
higher aSMA protein expression was observed at all
timepoints with an 8.1-fold increase measured at D20
(Sidak’s test, P < 0.001; n = 3 in each group; Fig. 1B),
which is higher than the fivefold threshold we set to
determine cell transdifferentiation.
In parallel, indirect IF was performed, where monolay-
ers of WI-38  TGFb grown on coverslips were fixed at
D20 and probed for vimentin (Fig. 1C and G) in combi-
nation with aSMA (Fig. 1D and H) and counterstained
with DAPI (Fig. 1E and I). Consistent with the western
blot analysis, indirect IF showed that WI-38 cells treated
with TGFb induced fibroblast to myofibroblast transdif-
ferentiation, indicated by the presence of positive aSMA
staining in the treated cells (Fig. 1H and J) and the pres-
ence of vimentin (Fig. 1G) similar to the untreated cells
(Fig. 1C). Taken together, these data suggest that treat-
ment of WI-38 with TGFb induced fibroblast to myofi-
broblast transdifferentiation at D20. Thus, following
experiments will describe specific differences observed
between fibroblasts (D1 WI-38  TGFb, D20 WI-38 -
TGFb) and transdifferentiated myofibroblasts (D20 WI-
38 + TGFb).
Effects of TGFb treatment on Smad2/3
expression in human lung fibroblasts and
transdifferentiated myofibroblasts
The mRNA levels of Smad2 and Smad3 were lower in
TGFb-treated fibroblast (D1 WI-38 + TGFb) compared
to untreated cells (D1 WI-38 - TGFb), with approxi-
mately two and sixfold decrease, respectively (Fig. 2A and
B). Expression of Smad2 and Smad3 genes was lower in
D20 WI-38 - TGFb compared to D1 WI-38 - TGFb,
whereas it remained similar in D1 WI-38 + TGFb com-
pared to D20 WI-38 + TGFb. Overall Smad2 mRNA
levels were higher and Smad3 mRNA levels lower in
myofibroblast (D20 WI-38 + TGFb) compared to their
respective control (D20 WI-38 - TGFb).
A similar pattern was observed in Smad2 and Smad3
protein expression with approximately 1.5 and a signifi-
cant, fourfold decreased expression in TGFb-treated
fibroblast (D1 WI-38 + TGFb) compared to untreated
fibroblasts (D1 WI-38 - TGFb), respectively (Fig. 2C,D).
Smad2 protein expression was unchanged in D20 WI-38 -
TGFb compared to D20 WI-38 + TGFb, whereas Smad3
expression was significantly decreased 4.1-fold in D20
WI-38 + TGFb compared to D20 WI-38 - TGFb (Two-
way ANOVA, P = 0.009; Sidak’s test, P = 0.036). These
results indicate that TGFb treatment induces changes in
Smad2 and Smad3 gene and protein expression patterns
in both fibroblasts and myofibroblasts. These changes in
protein and gene patterns might underlie a differential
TGFb-induced signaling pathway between fibroblast and
myofibroblast.
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TGFb-induced transdifferentiation
upregulates GRb expression in human lung
myofibroblasts
There was a significant change in GR mRNA levels in
TGFb-treated fibroblasts (D1 WI-38 + TGFb) compared
to untreated fibroblasts but this was not reflected in the
protein data (D1 WI-38 - TGFb; Fig. 3A and B). We
observed a 2.0-fold (nonsignificant) increase in GR
mRNA and total protein expression in TGFb-treated
myofibroblasts (D20 WI-38 + TGFb) compared to cells
left untreated (D20 WI-38 - TGFb; Fig. 3A and B). Inter-
estingly, a time-dependent increase in GR protein levels
was observed on TGFb treatment (D1 WI-38 + TGFb
compared to D20 WI-38 + TGFb; Fig. 3B). GR is known
to be expressed in two different isoforms (GRa and GRb)
due to differential splicing. Thus, we then sought to
establish which GR isoform was present in fibroblasts and
myofibroblasts (TGFb). We found that GRa was
present in both fibroblasts and myofibroblasts, regardless
of TGFb treatment (Fig. 3C). However, its expression
was increased 1.3 and 1.5-fold in TGFb-treated cells (D1
WI-38 + TGFb and D20 WI-38 + TGFb, respectively)
compared to their respective untreated controls (D1
WI-38-TGFb and D20 WI-38 - TGFb). Surprisingly, a
1.5-fold increase in GRb expression was also observed in
D1 WI-38 + TGFb compared to the untreated group (D1
WI-38 - TGFb, Fig. 3D). Moreover, GRb was significantly
expressed in D20 WI-38 + TGFb compared to D20
WI-38 - TGFb (Fig. 3D), with a 3.0-fold increase in the
TGFb-treated group compared to the untreated group at
D20 (Two-way ANOVA, P = 0.038, n = 3 in each treat-
ment group; Sidak’s test, P = 0.01). In summary,
increased GRa and GRb protein levels were mainly
observed in TGFb-treated cells, regardless of the cell phe-
notype (Fig. 3C and D). GRa and GRb proteins are the
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Figure 1. TGFb induces fibroblast to myofibroblast transdifferentiation. (A and B) Graphs show the relative protein expression for vimentin and
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active and the inactive isoforms of GR, respectively. Fur-
thermore, their respective level in cells is thought to be
involved in the glucocorticoids cell response. So, we then
focused on the ratio of GRa and GRb isoforms under our
experimental conditions. Interestingly, our results show
that despite an increase in both GRa and GRb isoforms,
GRb is the predominant isoform in TGFb-treated cells at
both D1 and D20 compared to their respective controls
(D1: GRb:GRa = 1.2; D20: GRb:GRa = 1.6; Fig. 3E).
We then investigated if GR localization was altered in
TGFb-treated cells. GR activation occurs in the cyto-
plasm, whereas its cellular action occurs in the nucleus,
via a translocation mechanism. As shown in Figure 3G–J,
GR nuclear localization was increased in TGFb-treated
myofibroblast phenotype cells (D20 WI-38 + TGFb) com-
pared to untreated cells (D20 WI-38 - TGFb). Image
analysis confirmed this observation, with a significant
difference in the relative fluorescence in the nucleus
compared to that in the cytoplasm (Fn/c) between treated
and untreated cells at D20 (Two-way ANOVA, P = 0.017,
n = 40; Fig. 3F, I and J). No significant change was
detected at D1 between TGFb-treated and -untreated
fibroblasts (Two-way ANOVA: P = 0. 71; n = 40;
Fig. 3F–H).
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Taken together, these data show that TGFb treatment
in WI-38 cells increases both GRa and GRb expression
irrespective of the time of treatment. Furthermore, we
demonstrate that GR is predominantly localized in the
nucleus of transdifferentiated myofibroblast upon TGFb
treatment.
Discussion
Fibroblast to myofibroblast transdifferentiation is one of
the pivotal events contributing to chronic asthma sequels,
which can result in severe impaired lung function. In this
study, we focus our attention on the key molecular com-
ponents involved in this transdifferentiation process. Our
data describe for the first time that TGFb treatment of
human lung fibroblast cell line (WI-38) induces fibroblast
to myofibroblast transdifferentiation. This mechanism is
accompanied by an altered TGFb signaling pathway,
involving at least Smad2/3. Importantly, we have also
demonstrated that GRb expression is increased in myofi-
broblasts, which is potentially responsible for the gluco-
corticoid resistance observed in severe asthma.
Airway remodeling in asthma
Airway remodeling is a key process leading to the pro-
gression of the symptoms associated with impaired pul-
monary function in asthma (Lazaar and Panettieri 2003;
Nihlberg et al. 2006; Yamauchi 2006). Airway remodeling
is defined as a response of the airway wall to repetitive
tissue injury leading to chronic inflammation and partial
repair process (Nihlberg et al. 2006; Postma and Timens
2006; Yamauchi 2006). This remodeling is characterized
by complex structural changes from cellular to molecular
level, altering airway wall function and its constituents,
among them: epithelium destruction, goblet cells hyper-
plasia, angiogenesis, and increase in basement membrane
thickness due to extracellular matrix deposition -the so-
called subepithelial fibrosis (McDonald 2001; Postma and
Timens 2006; Yamauchi 2006).
During asthma, inflammatory cells invade the airway
wall and in combination with airway wall cells, they
secrete inflammatory mediators like cytokines, including
TGFb, which is described as playing an important role in
regulating the airway remodeling process (Minshall et al.
1997; Panettieri 2003; Xu et al. 2003; Kay et al. 2004).
Indeed, TGFb has numerous effects depending on cellular
environment and cell condition (Makinde et al. 2007).
Among the different responses to TGFb stimulation, the
subepithelial layer fibrosis is one of the important pro-
cesses occurring during airway remodeling. This fibrosis
corresponds to the deposition of extracellular matrix
(ECM) leading to the thickening of the basement mem-
brane and the subepithelial layer.
TGFb induces fibroblast to myofibroblast
transdifferentiation
Myofibroblasts are almost absent in normal lung tissue. It
has been shown that fibroblast to myofibroblast transdif-
ferentiation is a critical event in the development of pro-
gressive lung fibrosis (Kuhn and McDonald 1991; Zhang
et al. 1994; Phan 2002). Indeed, fibroblast to myofibrob-
last transdifferentiation is an important process leading to
the subepithelial fibrosis (Makinde et al. 2007). TGFb is
classically described as an important fibrogenic factor
and it has been shown to trigger fibroblast to myofibrob-
last transdifferentiation in vitro as well as in vivo
(Ronnov-Jessen and Petersen 1993; Sime et al. 1997;
Hashimoto et al. 2001). Furthermore, studies show that
TGFb is involved in the pathogenesis of asthma. Indeed,
TGFb upregulation in asthmatic airways triggers fibroblast
to myofibroblast transdifferentiation (Redington et al.
1997; Vignola et al. 1997; Tillie-Leblond et al. 1999; Chu
et al. 2000).
Our data show that treatment with TGFb for 20 days
induces the expression of aSMA in WI-38 cell line (see
Fig. 1). This intermediate filament protein is classically
described as the principal feature in characterizing myofi-
broblastic phenotype (McAnulty 2007). Thus, we show
that TGFb induces WI-38 cell line transdifferentiation into
myofibroblasts. Our data demonstrate that WI-38 human
lung fibroblast cell line can be used as a model of
TGFb-mediated myofibroblast transdifferentiation. This
result is important as this model enables us to study
molecular aspects of fibroblast to myofibroblast transdif-
ferentiation-related diseases in vitro, and more particularly
TGFb-associated lung conditions, like asthma.
TGFb-induced Smad3 downregulation in
myofibroblast
The main intracellular signaling pathway of TGFb is well
characterized. This pathway involves the activation of the
transmembrane serine/threonine kinase TGFb receptor,
leading to Smad2 and Smad3 phosphorylation (receptor-
regulated Smads or R-Smads). They then form a hetero-
meric complex with Smad4 (common-mediator Smad or
Co-Smad), which translocates to the nucleus where it reg-
ulates the transcription of specific target genes. This path-
way is regulated by inhibitory Smads (including Smad7),
which inhibit Smad2/3 phosphorylation during TGFb
stimulation (Attisano and Wrana 2002; Shi and Massague
2003).
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Our results demonstrate that TGFb differentially regu-
lates Smad2 and Smad3 expression in WI-38 cells. Indeed,
Smad2 expression is not affected by TGFb at D20 (see
Fig. 2A and C). Whereas, Smad3 gene and protein expres-
sions are strongly downregulated following TGFb treat-
ment at both D1 and D20 (see Fig. 2B and D).
Hu et al. (2003) have shown that TGFb treatment
increases Smad3 expression in primary rat lung fibroblasts.
Furthermore, Gu et al. (2007) found that TGFb-induced
aSMA gene upregulation is under the control of Smad3
in vitro. In our study, we show that aSMA gene expression
is increased in TGFb-treated cells (data not shown), similar
to its protein expression (Fig. 1). This would suggest a role
for Smad3 in fibroblast to myofibroblast transdifferentia-
tion in WI-38 cells. Interestingly, our data indicate a
decrease in Smad3 expression following TGFb treatment
(see Fig. 2D). This discrepancy with previous studies can
be explained by the complex nature of the Smads signaling
pathway. Indeed, aSMA gene promoter is also under the
control of Smad2 in rodent vascular cells treated with
TGFb (Corjay et al. 1989; Mack and Owens 1999). Our
data do not indicate changes in Smad2 protein in TGFb-
transdifferentiated myofibroblast at D20. So, we can
hypothesize that aSMA expression during TGFb treatment
is mediated through Smad2. Furthermore, it is also possible
that other TGFb-activated signaling pathways may con-
tribute to the transcriptional regulation of aSMA in myofi-
broblast. Indeed, it has been described that non-Smad
pathways, such as the phosphatidylinositol 3-kinase
(PI3K)/Akt pathway, participates in TGFb-induced myofi-
broblast formation during epithelial to mesenchymal tran-
sition (Kim et al. 2006; Lamouille and Derynck 2007).
Further experiments should be performed in order to clar-
ify the cellular pathway(s) involved in the fibroblast to
myofibroblast transdifferentiation and more precisely in
the regulation of aSMA gene expression.
Glucocorticoid receptor upregulation in
TGFb induced myofibroblast
Glucocorticoids play an important role in many physio-
logical functions essential for life, such as growth, inflam-
mation, tissue repair, reproduction, metabolism, immune,
cardiovascular, and nervous system functions (Kadmiel
and Cidlowski 2013). In the cell, glucocorticoid responses
are mediated by the activation and nuclear translocation
of the cytoplasmic glucocorticoid receptor (GR). This
activated receptor then regulates the transcription of tar-
get genes. In humans, alternate splicing of GR mRNA
results in the synthesis of two functionally different iso-
forms. GRa is known to be the predominant isoform
responsible for GR cellular response (Reichardt and
Schutz 1998). While GRb is a dominant negative isoform
of GR, whose presence induces inhibition of glucocorti-
coid activity (Bamberger et al. 1995). Thus, the cellular
ratio of the two isoforms of GR could influence the cellu-
lar responses to glucocorticoids.
Studies show that GR is expressed in lung fibroblasts
as well as myofibroblasts (Eickelberg et al. 1999; Baouz
et al. 2005). Consistent with these studies, our data
indicate that GR is expressed in WI-38 cell line regard-
less of time and TGFb treatment. However, TGFb treat-
ment induces a 2.0 and 1.5-fold increase in GR mRNA
and protein expression at D20, respectively (Fig. 3A and
B). Our results demonstrate for the first time a differen-
tial expression of GR in WI-38 fibroblast and myofi-
broblast. The expression of GR in cells, especially in
fibroblasts and myofibroblasts, is important for cell
homeostasis. Unfortunately, there is a lack of evidence
correlating the observed increase in GR expression and
fibroblast to myofibroblast transdifferentiation. Further
investigation is required to elucidate the cellular mecha-
nisms involved in GR regulation during TGFb-induced
fibroblast to myofibroblast transdifferentiation. Thus,
our study leads to important questions on the role of
GR and its regulation in myofibroblast-related disease
(such as asthma).
Our data show a significant increase in GR nuclear
localization in TGFb-transdifferentiated myofibroblast
(D20, Fig. 3E–I). We also show that GRb isoform expres-
sion is strongly increased in transdifferentiated myofi-
broblast (D20, Fig. 3D). While we do not directly
demonstrate the nature of the nuclear GR isoform, it is
tempting to postulate that the observed increased GR in
the nucleus is due to GRb isoform. Indeed, studies show
that GRb isoform is constitutively localized in the nucleus
of cells (Lewis-Tuffin and Cidlowski 2006; Kino et al.
2009). In our study, the accumulation of GRb in the
nucleus could be due to (1) a decrease in GRb degrada-
tion, (2) an increase in GRb expression and/or 3) an
increase in nucleo-cytoplasmic transport of this protein.
Current research in the group is focused on assessing
how TGFb regulates GR isoform expression and activity
in the WI-38 cell line.
All together, our data indicate that TGFb-treated WI-
38 cell line is a relevant model to investigate the
cellular and molecular mechanisms involved in fibrob-
last to myofibroblast transdifferentiation occurring in
asthma.
Furthermore, our data indicate that GRb expression is
predominant compared to GRa in TGFb-transdifferen-
tiated myofibroblast, as indicated by the increase in GRb:
GRa ratio (D20, Fig. 3E). Interestingly, numerous studies
demonstrate that increased GRb is associated with lung
diseases, such as asthma (Hamid et al. 1999; Christodou-
lopoulos et al. 2000; Sousa et al. 2000; Pujols et al. 2004;
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Goleva et al. 2006). These studies also indicate that
increased expression of the nonfunctional GRb isoform
may account for glucocorticoid insensitivity in inflamma-
tory diseases, among them asthma (Leung et al. 1997;
Hamid et al. 1999; Sousa et al. 2000; Goleva et al. 2006).
We can therefore hypothesize that TGFb-transdifferen-
tiated myofibroblasts from WI-38 cell line present a resis-
tance to glucocorticoid treatment. This cellular model
represents a critical tool in the understanding of the
underlying mechanisms of glucocorticoid insensitivity
observed in steroid-resistant severe asthma.
Conclusion
In conclusion, the results of this study show that TGFb
induces (1) fibroblast to myofibroblast transdifferentiation
in a human lung fibroblast cell line, (2) decrease in
Smad3 expression in myofibroblasts, 3) increase in GRb
expression in myofibroblasts.
TGFb plays an important role in airway remodeling.
This remodeling involves transdifferentiation of fibrob-
lasts into myofibroblasts, a key event initiating tissue
fibrosis observed in many lung diseases, such as
asthma. This transdifferentiation mechanism implicates
Smad3, a component of the TGFb signaling pathway.
While Smad3 seems to be affected during WI-38 myofi-
broblast transdifferentiation, the exact role of Smad3 in
fibroblast to myofibroblast transdifferentiation is still
not fully understood. Attention has been given to a
potential role for GR to inhibit TGFb signaling path-
way through a regulation of Smad3 (Song et al. 1999).
So, further studies should focus on the interaction
between TGFb, Smad3, GR and possible glucocorticoid
insensitivity in WI-38 human lung fibroblast cell line to
provide greater insights in asthma-related fibroblast to
myofibroblast transdifferentiation and glucocorticoid
resistance.
The human lung fibroblast WI-38 cell line used in this
study represents a promising model to study lung diseases
and more particularly asthma and glucocorticoid-resistant
asthma in providing better understanding in the cellular
and molecular aspects of such disease after myofibroblast
transdifferentiation.
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